Person
Kazuto Fukunaga
This person is no longer with EPFL
About this result
This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.
Related publications (4)
Please note that this is not a complete list of this person’s publications. It includes only semantically relevant works. For a full list, please refer to Infoscience.
Targeted antibody and cytokine cancer immunotherapies through collagen affinity
Jeffrey Alan Hubbell, Melody Swartz, Seung Tae Lee, Lambert Charles François Potin, Jun Ishihara, Kazuto Fukunaga, Michal Mateusz Raczy
Cancer immunotherapy with immune checkpoint inhibitors (CPIs) and interleukin-2 (IL-2) has demonstrated clinical efficacy but is frequently accompanied with severe adverse events caused by excessive and systemic immune system activation. Here, we addressed ...
AMER ASSOC ADVANCEMENT SCIENCE2019The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing
Matthias Lütolf, Jeffrey Alan Hubbell, Yoji Tabata, Jun Ishihara, Kazuto Fukunaga
During wound healing, the distribution, availability, and signaling of growth factors (GFs) are orchestrated by their binding to extracellular matrix components in the wound microenvironment. Extracellular matrix proteins have been shown to modulate angiog ...
AMER SOC HEMATOLOGY2019Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity
Jeffrey Alan Hubbell, Melody Swartz, Lambert Charles François Potin, Martina Damo, Jun Ishihara, Kazuto Fukunaga
CD40 is an immune costimulatory receptor expressed by antigen-presenting cells. Agonistic anti-CD40 antibodies have demonstrated considerable antitumor effects yet can also elicit serious treatment-related adverse events, such as liver toxicity, including ...
AMER ASSOC CANCER RESEARCH2018